Medibank Introduces Comprehensive At-Home Alcohol and Drug Detox Program in Partnership with Clean Slate Clinic Medibank has announced the launch of its new Alcohol and Drug Detox at Home program—an…
Partnership targets innovative mRNA therapy to reduce dangerous atherosclerotic plaque. AGC Biologics has announced a new partnership with Repair Biotechnologies aimed at advancing an innovative mRNA therapeutic designed to combat…
Neurogene Reports Third Quarter 2025 Financial Results and Provides Comprehensive Clinical and Corporate Updates a clinical-stage biotechnology company dedicated to delivering transformative genetic medicines for patients with rare neurological disorders,…
AV Laboratories Redefines Cellular Renewal Through Molecular Biotechnology AV Laboratories is ushering in a new era of skincare, one where biotechnology moves beyond the clinical bench and becomes an essential…
Indivi Secures CHF 15 Million to Advance Biomarker Discovery in Alzheimer’s and Neuroscience Drug Development Indivi, an independent TechBio company pioneering precision medicine solutions for neuroscience, today announced the successful…
Biomunex to Present Breakthrough Preclinical Data on Its MAIT Engager Immuno-Oncology Platform at the 2025 SITC Annual Meeting Biomunex Pharmaceuticals, a French biopharmaceutical company advancing the frontiers of cancer immunotherapy…
BioTalent Canada Welcomes Federal Government’s Three-Year Extension of the Student Work Placement Program, Strengthening Canada’s Workforce and Economic Future BioTalent Canada has officially applauded the Government of Canada’s decision, announced…
Zai Lab Reports Promising Phase 1 Results for Zocilurtatug Pelitecan in Extensive-Stage Small Cell Lung Cancer, Launches Global Phase 3 Trial Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) has released…
Pulse Biosciences Enrolls First Patient in NANOCLAMP AF Study, Marking Major Milestone in Atrial Fibrillation Treatment Innovation Pulse Biosciences, Inc. (Nasdaq: PLSE), a company pioneering next-generation medical technologies through its…
Coya Therapeutics Prices Upsized $20 Million Public Offering to Advance Treg-Based Therapies for Neurodegenerative Diseases Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company pioneering biologic therapies designed to enhance…
Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Receives FDA Authorization Emalex Biosciences, a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodevelopmental and neurological disorders, today…
Orca Bio’s Orca-T Receives FDA Priority Review for Treatment of Blood Cancers, Marking Major Step Toward Potential First-in-Class Therapy Orca Bio, a late-stage biotechnology company pioneering high-precision cell therapies to…